MedTrace Logo

Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

NCT00517868 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-08-23

Study results available
· View outcomes & findings →

Summary

A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.

Conditions

  • Painful Bladder Syndrome
  • Interstitial Cystitis
  • Bladder Pain Syndrome

Interventions

DRUG

URG101

Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.

DRUG

Placebo

Liquid formulation without active URG101 drug components

Sponsors & Collaborators

  • Urigen

    lead INDUSTRY

Principal Investigators

  • Jeff Proctor, M.D. · Georgia Urology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-28
Primary Completion
2008-02-28
Completion
2008-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00517868 on ClinicalTrials.gov